A Prediction Model of Basic Blood Volume Based on Ultrasound
Launched by SHANGHAI 6TH PEOPLE'S HOSPITAL · Apr 26, 2025
Trial Information
Current as of July 25, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new way to assess blood volume in patients by combining two advanced techniques: a hemodynamic monitoring system called LiDCO and a non-invasive ultrasound method that looks at the inferior vena cava (IVC), a large vein that carries blood to the heart. The goal is to create a predictive model that can give a more accurate picture of a patient’s blood volume, which is especially important in surgery and critical care. Correctly managing blood volume is vital because too little or too much blood can lead to serious health problems.
To participate in this study, you need to be between 18 and 75 years old, have a body mass index (BMI) between 18 and 30, and be in good health according to specific medical guidelines. You will be asked to sign a consent form to join the study. If eligible, you can expect to undergo monitoring using the LiDCO system and IVC ultrasound to help doctors better understand your blood volume status. It’s important to know that certain medical conditions, like severe heart or liver problems, or if you are pregnant, may exclude you from this trial. This research aims to improve how doctors manage blood volume, potentially leading to better outcomes for patients undergoing surgery or in critical care situations.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Agree to join this study and sign the informed consent form;
- • Age between 18 and 75 years old (inclusive);
- • BMI (body mass index) is between 18 and 30 kg/m2;
- • American Society of Anesthesiologists (ASA) grades I-II
- Exclusion Criteria:
- • Preoperative hemoglobin (Hb) \<10g/dl
- • Cardiac dysfunction (NYHA class III-IV), respiratory dysfunction (ATS class 2-4), history of liver and kidney dysfunction (such as transaminase / albumin / bilirubin abnormalities, hepatitis history, serum creatinine / urea nitrogen rise, etc.), nervous system abnormalities (those who cannot cooperate due to stroke or its sequelae, Alzheimer, etc.);
- • The ultrasonic display of inferior vena cava, internal jugular vein or subclavian vein is extremely poor, venous thrombosis or anatomical abnormalities;
- • Multiple injury with chest, abdomen or brain;
- • Pregnant woman
About Shanghai 6th People's Hospital
Shanghai 6th People's Hospital is a leading medical institution in China, renowned for its commitment to advancing healthcare through innovative research and clinical trials. As a prominent sponsor of clinical studies, the hospital focuses on a wide range of therapeutic areas, striving to enhance patient outcomes and contribute to medical knowledge. With a dedicated team of experienced researchers and clinicians, Shanghai 6th People's Hospital emphasizes rigorous scientific methodology and ethical standards, ensuring that all trials are conducted with the utmost integrity and patient safety in mind. Through collaboration with various stakeholders, the hospital aims to bridge the gap between clinical research and real-world application, ultimately improving healthcare delivery both locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shanghai, Shanghai, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported